FansUnite Entertainment Inc Announces Uplist to Trade on the OTCQB Market

FansUnite Entertainment Inc (CSE: FANS) (OTCQB: FUNFF) ("FansUnite" or the "Company"), a sports and entertainment company, focusing on its technology related to regulated online sports betting and related products, is pleased to announce it has received approval to officially "uplist" from the PinkĀ® market to the OTCQB Venture Market ("OTCQB"). The common shares will trade under the symbol FUNFF effective as of the opening of the market on November 16, 2020.

"We have seen an increased interest from American investors as the online betting space gains traction worldwide," said Scott Burton, CEO of FansUnite Entertainment. "By upgrading our ticker, we will have increased visibility and exposure to a broader investment community. As we continue to execute on our vision of becoming a global iGaming leader, we are excited to showcase our achievements to a growing base of U.S. and international investors."

The OTCQB is a Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on https://www.otcmarkets.com.

The move of FansUnite's shares from Pink Market to OTCQB will not impact or require additional action from shareholders. The stock continues to trade on OTC but now will be accessible through the middle-tier OTC offering. In addition, there will be no change of trading under the Canadian Securities Exchange symbol FANS.

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
ir@fansunite.com
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami President of FansUnite
darius@fansunite.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute "forward-ā€Žlooking information" under Canadian securities legislation. Generally, forward-looking information can be ā€Židentified by the use of forward-looking terminology such as "believes," "belief," "expects," "intends," ā€Žā€Ž"anticipates," "potential," "should," "may," "will," "plans," "continue" or similar expressions to be uncertain ā€Žand forward-looking. Forward-looking statements may include, without limitation, statements relating to ā€Žfuture outlook and anticipated events such as:; ā€Žincreased visibility and exposure resulting from trading on the OTCQB; ā€Žgrowth of the Company's base of US and international investors;ā€Ž the ā€ŽCompany's unique portfolio of assets; and discussion of future plans, projections, objectives, estimates ā€Žand forecasts and the timing related thereto. Forward-looking statements are based on the Company's ā€Žestimates and are subject to known and unknown risks, uncertainties and other factors that may cause the ā€Žactual results, level of activity, performance or achievements of FansUnite to be materially different from ā€Žthose expressed or implied by such forward-looking statements or forward-looking information. Additional ā€Žinformation regarding the risks and uncertainties relating to the Company's business are contained under ā€Žthe heading "Risk Factors" in the Company's Non-Offering Prospectus dated March 27, 2020 filed on its ā€Žissuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel ā€Žcoronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence ā€Žof macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking ā€Žstatements and forward-looking information. The forward-looking statements in this news release are made ā€Žas of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-ā€Žlooking statements or forward-looking information, whether as a result of new information, future events or ā€Žotherwise, except as required by applicable securities laws.ā€Ž

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68235

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairmanā€™s Address 2024 Annual General Meeting ā€“ 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limitedā€™s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR ā€“ Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

Ɨ